Oregon Public Employees Retirement Fund Buys New Shares in Indivior PLC $INDV

Oregon Public Employees Retirement Fund bought a new stake in shares of Indivior PLC (NASDAQ:INDV) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 28,600 shares of the company’s stock, valued at approximately $1,026,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Salomon & Ludwin LLC bought a new position in shares of Indivior during the 4th quarter valued at $30,000. Harbor Capital Advisors Inc. grew its holdings in shares of Indivior by 309.9% during the 4th quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock valued at $37,000 after purchasing an additional 781 shares during the last quarter. CWM LLC bought a new position in shares of Indivior during the 3rd quarter valued at $25,000. Quarry LP bought a new position in shares of Indivior during the 3rd quarter valued at $26,000. Finally, GAMMA Investing LLC grew its holdings in shares of Indivior by 544.6% during the 4th quarter. GAMMA Investing LLC now owns 1,199 shares of the company’s stock valued at $43,000 after purchasing an additional 1,013 shares during the last quarter. Institutional investors own 60.33% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on INDV shares. Weiss Ratings lowered shares of Indivior from a “hold (c+)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. Zacks Research raised shares of Indivior from a “hold” rating to a “strong-buy” rating in a report on Monday, March 16th. Finally, Northland Securities set a $50.00 target price on shares of Indivior in a report on Tuesday, January 20th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $39.33.

Insider Transactions at Indivior

In other news, Director Stuart A. Kingsley purchased 940 shares of the business’s stock in a transaction on Friday, March 6th. The shares were acquired at an average price of $31.86 per share, with a total value of $29,948.40. Following the acquisition, the director directly owned 5,582 shares in the company, valued at approximately $177,842.52. The trade was a 20.25% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.74% of the stock is currently owned by company insiders.

Indivior Stock Down 0.6%

Shares of Indivior stock opened at $36.54 on Tuesday. The firm has a market cap of $4.46 billion, a PE ratio of 18.74 and a beta of 0.90. Indivior PLC has a 12-month low of $11.06 and a 12-month high of $41.00. The company’s fifty day simple moving average is $33.02 and its two-hundred day simple moving average is $33.50.

Indivior (NASDAQ:INDV) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $0.96 earnings per share (EPS) for the quarter. The business had revenue of $317.00 million for the quarter. Indivior had a net margin of 19.44% and a negative return on equity of 219.26%. As a group, sell-side analysts expect that Indivior PLC will post 3.35 earnings per share for the current fiscal year.

Indivior Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.